Imaging gliomas with positron emission tomography and single-photon emission computed tomography.

Over the last two decades the large volume of research involving various brain tracers has shed invaluable light on the pathophysiology of cerebral neoplasms. Yet the question remains as to how best to incorporate this newly acquired insight into the clinical context. Thallium is the most studied radiotracer with the longest track record. Many, but not all studies, show a relationship between (201)Tl uptake and tumor grade. Due to the overlap between tumor uptake and histologic grades, (201)Tl cannot be used as the sole noninvasive diagnostic or prognostic tool in brain tumor patients. However, it may help differentiating a high-grade tumor recurrence from radiation necrosis. MIBI is theoretically a better imaging agent than (201)Tl but it has not convincingly been shown to differentiate tumors according to grade. MDR-1 gene expression as demonstrated by MIBI does not correlate with chemoresistance in high grade gliomas. Currently, MIBI's clinical role in brain tumor imaging has yet to be defined. IMT, a radio-labeled amino acid analog, may be useful for identifying postoperative tumor recurrence and, in this application, appears to be a cheaper, more widely available tool than positron emission tomography (PET). However, its ability to accurately identify tumor grade is limited. 18 F-2-Fluoro-2-deoxy-d-glucose (FDG) PET predicts tumor grade, and the metabolic activity of brain tumors has a prognostic significance. Whether FDG uptake has an independent prognostic value above that of histology remains debated. FDG-PET is effective in differentiating recurrent tumor from radiation necrosis for high-grade tumors, but has limited value in defining the extent of tumor involvement and recurrence of low-grade lesions. Amino-acid tracers, such as MET, perform better for this purpose and thus play a complementary role to FDG. Given the poor prognosis of patients with gliomas, particularly with high-grade lesions, the overall clinical utility of single photon emission computed tomography (SPECT) and PET in characterizing recurrent lesions remains dependent on the availability of effective treatments. These tools are thus mostly suited to the evaluation of treatment response in experimental protocols designed to improve the patients' outcome.

[1]  H Evans,et al.  Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography:a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas , 2000, British Journal of Cancer.

[2]  M. Mehta,et al.  Early changes in tumor metabolism after treatment: the effects of stereotactic radiotherapy. , 1991, International journal of radiation oncology, biology, physics.

[3]  S. Treves,et al.  Thallium-201 versus technetium-99m-MIBI SPECT in evaluation of childhood brain tumors: a within-subject comparison. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  A. Luxen,et al.  Use of positron emission tomography (PET) in stereotactic conditions for brain biopsy , 1995, Acta Neurochirurgica.

[5]  O. Schober,et al.  Non-invasive grading of primary brain tumours: Results of a comparative study between SPET with123I-α-methyl tyrosine and PET with18F-deoxyglucose , 1997, European Journal of Nuclear Medicine.

[6]  M. Marzola,et al.  SPET imaging of intracranial tumours with 99Tcm-sestamibi , 1995, Nuclear medicine communications.

[7]  R. Plevin,et al.  Growth factors, mitogens, oncogenes and the regulation of glucose transport. , 1993, Cellular signalling.

[8]  H. Atkins,et al.  Thallium-201 brain tumor imaging: a comparative study with pathologic correlation. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  M. Berger,et al.  2-[C-11]thymidine imaging of malignant brain tumors. , 1999, Cancer research.

[10]  W D Heiss,et al.  FDG‐PET as a Prognostic Indicator in Radiochemotherapy of Glioblastoma , 1993, Journal of computer assisted tomography.

[11]  J. Unterrainer,et al.  Clinical relevance of 201Tl-chloride SPET in the differential diagnosis of brain tumours. , 1998, Nuclear medicine communications.

[12]  F Shishido,et al.  Cerebral glioma: evaluation with methionine PET. , 1993, Radiology.

[13]  U. Spetzger,et al.  Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses , 2001, European Journal of Nuclear Medicine.

[14]  K Herholz,et al.  Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. , 1993, Journal of neurosurgery.

[15]  C. Kufta,et al.  Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. , 1987, AJR. American journal of roentgenology.

[16]  G. Slegers,et al.  Uptake of 13N-ammonia by human tumours as studied by positron emission tomography. , 1982, The British journal of radiology.

[17]  A. Soricelli,et al.  Technetium-99m-tetrofosmin uptake in brain tumors by SPECT: comparison with thallium-201 imaging. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  R. Brooks,et al.  Glycolytic rate (PET) and contrast enhancement (CT) in human cerebral gliomas. , 1983, AJNR. American journal of neuroradiology.

[19]  S. Goldman,et al.  Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. , 1996, Neurosurgery.

[20]  A. Alavi,et al.  Can the standardized uptake value characterize primary brain tumors on FDG-PET? , 1999, European Journal of Nuclear Medicine.

[21]  N. Shinoura,et al.  Brain tumors: detection with C-11 choline PET. , 1997, Radiology.

[22]  M. Lonchampt,et al.  Diagnosis of cerebral lesions by Thallium 201. , 1978, Radiology.

[23]  Mary Ann Moran,et al.  Synthesis and Evaluation , 1986 .

[24]  K. Kunishio,et al.  Comparison of 99Tcm-MIBI with 201Tl chloride SPET in patients with malignant brain tumours , 2001, Nuclear medicine communications.

[25]  K. Endo,et al.  Clinical evaluation of thallium-201 SPECT in supratentorial gliomas: relationship to histologic grade, prognosis and proliferative activities. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  M. Senda,et al.  A comparative study on protein incorporation of L-[methyl-3H]methionine, L-[1-14C]leucine and L-2-[18F]fluorotyrosine in tumor bearing mice. , 1993, Nuclear medicine and biology.

[27]  J A Frank,et al.  Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. , 1992, Radiology.

[28]  A. Bockisch,et al.  Imaging of brain tumors with L-3-[123I]iodo-alpha-methyl tyrosine and SPECT. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  R. Gilden,et al.  Evidence for a functional change in the plasma membrane of murine sarcoma virus-infected mouse embryo cells. Transport and transport-associated phosphorylation of 14C-2-deoxy-D-glucose. , 1970, The Journal of biological chemistry.

[30]  A. Luxen,et al.  Fast [18F]FDG synthesis by alkaline hydrolysis on a low polarity solid phase support , 2002 .

[31]  R. Blasberg,et al.  Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. , 2000, Cancer research.

[32]  F. Shishido,et al.  Clinical Value of Pet with 18F-Fluorodeoxyglucose and L-Methyl-11C-Methionine for Diagnosis of Recurrent Brain Tumor and Radiation Injury , 1991, Acta radiologica.

[33]  M. Schwaiger,et al.  Correlation Between Postoperative 3-[123I]Iodo-l-α-Methyltyrosine Uptake and Survival in Patients with Gliomas , 2001 .

[34]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[35]  K. Langen,et al.  Transport mechanisms of 3-[123I]iodo-alpha-methyl-L-tyrosine in a human glioma cell line: comparison with [3H]methyl]-L-methionine. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  J. Hatazawa,et al.  The accumulation of11C-methionine in cerebral glioma patients studied with PET , 2005, Acta Neurochirurgica.

[37]  J Grierson,et al.  Utilization of labeled thymidine in DNA synthesis: studies for PET. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  A. Alavi,et al.  PET versus SPECT in distinguishing radiation necrosis from tumor recurrence in the brain. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  Barry H. Smith,et al.  Issues in the in vivo measurement of glucose metabolism of human central nervous system tumors , 1984, Annals of neurology.

[40]  J. Hatazawa,et al.  Tumor detection with carbon-11-labelled amino acids , 1984, European Journal of Nuclear Medicine.

[41]  L. Deangelis,et al.  Brain Tumors , 2019, Imaging Gliomas After Treatment.

[42]  Abass Alavi,et al.  Positron emission tomography in patients with glioma a predictor of prognosis , 1988, Cancer.

[43]  J. Villemure,et al.  Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET , 1991, Journal of Neuro-Oncology.

[44]  W. J. Oakes,et al.  FDG-PET in pediatric posterior fossa brain tumors. , 1992, Journal of computer assisted tomography.

[45]  A. Jacobs,et al.  Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. , 1999, Neoplasia.

[46]  G. Weber Enzymology of cancer cells (second of two parts). , 1977, The New England journal of medicine.

[47]  I Lemahieu,et al.  [Methyl-11C]thymidine positron emission tomography in tumoral and non-tumoral cerebral lesions. , 1999, Acta neurologica Belgica.

[48]  F. Wrenn,et al.  The use of positron-emitting radioisotopes for the localization of brain tumors. , 1951, Science.

[49]  Tomio Inoue,et al.  Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging , 2001, European Journal of Nuclear Medicine.

[50]  O. Schober,et al.  Diagnosis of recurrent glioma with SPECT and iodine-123-α-methyl tyrosine , 1998 .

[51]  G. Reifenberger,et al.  3-[123I]Iodo-α-methyl-L-tyrosine uptake in cerebral gliomas: relationship to histological grading and prognosis , 2001, European Journal of Nuclear Medicine.

[52]  J. Moringlane,et al.  Evaluation of l-3-[123I]iodo-α-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy , 1999, European Journal of Nuclear Medicine.

[53]  Jean Charles Gilbert,et al.  Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  F. Soussaline,et al.  Brain tumor protein synthesis and histological grades: A study by positron emission tomography (PET) with C11-L-Methionine , 2004, Journal of Neuro-Oncology.

[55]  D. Ingvar,et al.  Measurement of regional cerebral blood flow. , 1977, International journal of neurology.

[56]  M. Sasaki,et al.  A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours , 1998, European Journal of Nuclear Medicine.

[57]  A. Thiel,et al.  11C-methionine PET for differential diagnosis of low-grade gliomas , 1998, Neurology.

[58]  J. Hornaday,et al.  Cancer Facts & Figures 2004 , 2004 .

[59]  G. Lenzi,et al.  Relationship between thallium-201 uptake by supratentorial glioblastomas and their morphological characteristics on magnetic resonance imaging , 1996, European Journal of Nuclear Medicine.

[60]  R. Coleman,et al.  FDG-PET in the selection of brain lesions for biopsy. , 1991, Journal of computer assisted tomography.

[61]  Otto Warburn,et al.  THE METABOLISM OF TUMORS , 1931 .

[62]  J. Moringlane,et al.  Initial evaluation of the feasibility of single photon emission tomography with p-[123I]iodo-L-phenylalanine for routine brain tumour imaging , 2002, Nuclear medicine communications.

[63]  O. Schober,et al.  Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[64]  J. Smirniotopoulos The new WHO classification of brain tumors. , 1999, Neuroimaging clinics of North America.

[65]  O. Schober,et al.  Uptake of iodine-123-α-methyl tyrosine by gliomas and non-neoplastic brain lesions , 1996, European Journal of Nuclear Medicine.

[66]  T. Hölzer,et al.  The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using f-18-fluorodeoxyglucose and c-11-L-methylmethionine. , 1997, Neurosurgery.

[67]  S. Nelson,et al.  Imaging of brain tumors after therapy. , 1999, Neuroimaging clinics of North America.

[68]  P. Courtheoux,et al.  The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. , 1997, Neurosurgery.

[69]  K. Leenders,et al.  Alteration of blood-brain barrier in human brain tumors: comparison of [18F]fluorodeoxyglucose, [11C]methionine and rubidium-82 using PET , 1995, Journal of the Neurological Sciences.

[70]  J. Dobkin,et al.  Glucose uptake by gliomas after treatment. A positron emission tomographic study. , 1989, Archives of neurology.

[71]  A. Bockisch,et al.  Imaging of Brain Tumors with L-3-[123I]Iodo-α-Methyl Tyrosine and SPECT , 1989 .

[72]  D. Podoloff,et al.  Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. , 1992, Radiographics : a review publication of the Radiological Society of North America, Inc.

[73]  G. di Chiro,et al.  Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. , 1989, Neurosurgery.

[74]  K Wienhard,et al.  Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[75]  R A Brooks,et al.  Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography , 1982, Neurology.

[76]  S. Goldman,et al.  FDG-PET as a Prognostic Factor in High-grade Astrocytoma , 2000, Journal of Neuro-Oncology.

[77]  H. Hoshi,et al.  Thallium-201 SPECT for predicting histological types of meningiomas. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[78]  M. Schwaiger,et al.  Correlation between postoperative 3-[(123)I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[79]  A. Alavi,et al.  New grading system of cerebral gliomas using positron emisson tomography with F-18 fluorodeoxyglucose , 1991, Journal of Neuro-Oncology.

[80]  F. Barral,et al.  Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy , 1998, European Journal of Nuclear Medicine.

[81]  T Greitz,et al.  Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. , 1983, Journal of computer assisted tomography.

[82]  S. Larson,et al.  Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. , 2001, Cancer research.

[83]  J. Martín,et al.  Sensitivity and specificity of thallium-201 single-photon emission tomography in the functional detection and differential diagnosis of brain tumours , 1994, European Journal of Nuclear Medicine.

[84]  C. Crouzel,et al.  Amino acids for the measurement of protein synthesis in vivo by PET. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[85]  R. G. Manning,et al.  Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. , 1982, Radiology.

[86]  F. Berthold,et al.  In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment , 1993, Cancer.

[87]  D Sun,et al.  Clinical application of 201Tl SPECT imaging of brain tumors. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[88]  J C Mazziotta,et al.  Thallium-201 SPECT imaging of brain tumors: methods and results. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[89]  H. Herzog,et al.  3-[123I]iodo-alpha-methyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[90]  A. Lilja,et al.  Dynamic study of supratentorial gliomas with L-methyl-11C-methionine and positron emission tomography. , 1985, AJNR. American journal of neuroradiology.

[91]  A. Friedman,et al.  Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography , 1991, Annals of neurology.

[92]  C. Degueldre,et al.  Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[93]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[94]  S. Jinnouchi,et al.  Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET? , 1998, European Journal of Nuclear Medicine.

[95]  K. Kubota,et al.  Effects of radiotherapy on the cellular uptake of carbon-14 labeled L-methionine in tumor tissue. , 1995, Nuclear medicine and biology.

[96]  P. Ricci Imaging of adult brain tumors. , 1999, Neuroimaging clinics of North America.

[97]  O. Witte,et al.  Positron emission tomography with injection of methionine as a prognostic factor in glioma. , 2001, Journal of neurosurgery.

[98]  R. Shigemoto,et al.  Distribution of the glucose transporters in human brain tumors. , 1992, Cancer research.

[99]  R. Blasberg,et al.  Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[100]  M. Berger,et al.  Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. , 2001, Journal of neurosurgery.

[101]  V. Sturm,et al.  11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. , 1997, Stereotactic and functional neurosurgery.

[102]  K. Ishiwata,et al.  Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[103]  D. Kinzel,et al.  Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[104]  M. Senda,et al.  Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[105]  Derlon Jm,et al.  [11C]L-methionine uptake in gliomas. , 1989 .

[106]  M. Shigemori,et al.  Thallium-201 in brain tumors: relationship between tumor cell activity in astrocytic tumor and proliferating cell nuclear antigen. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[107]  A. Wolf,et al.  Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[108]  K. L. Leenders,et al.  PET: Blood flow and oxygen consumption in brain tumors , 2005, Journal of Neuro-Oncology.

[109]  O. Schober,et al.  Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions. , 1996, European journal of nuclear medicine.

[110]  R. Coleman,et al.  Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[111]  T. Borght,et al.  Brain tumor imaging with PET and 2-[carbon-11]thymidine. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.